Regencell Bioscience Holdings (RGC) Total Current Liabilities (2020 - 2025)

Regencell Bioscience Holdings has reported Total Current Liabilities for 6 years, with the latest figure at $1.7 million in Q4 2025.

• For the quarter ending Q4 2025, Total Current Liabilities changed N/A year-over-year to $1.7 million; the trailing twelve-month figure through Dec 2025 stood at $1.7 million (changed N/A YoY), and the FY2025 full-year result was $663673.0, up 242.85% from the prior year.
• Total Current Liabilities for Q4 2025 stood at $1.7 million, up from $663673.0 in the prior quarter.
• The five-year high for Total Current Liabilities was $4.3 million in Q2 2021, with the low at $193578.0 in Q2 2024.
• Historically, Total Current Liabilities has averaged $1.3 million across 5 years, with a median of $635293.5 in 2023.
• Annual changes were most pronounced in 2022 — Total Current Liabilities plunged 86.68% — and 2025, when it surged 242.85%.
• Regencell Bioscience Holdings' Total Current Liabilities stood at $4.3 million in 2021, then sank by 86.68% to $577764.0 in 2022, then advanced by 5.05% to $606914.0 in 2023, then slumped by 68.1% to $193578.0 in 2024, then jumped by 760.54% to $1.7 million in 2025.
• The last three Total Current Liabilities figures came in at $1.7 million (Q4 2025), $663673.0 (Q2 2025), and $193578.0 (Q2 2024), per Business Quant data.